| Developing new products in cystic fibrosis: Needs and obstacles for activities of small and middle-sized companies. | |
| | |
MedLine Citation:
|
PMID: 21658629 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Small and middle-sized enterprises (SMEs) can make important contributions to medical progress through the development of new safe and effective drugs that address the greatest unmet needs of patients. Regulatory inconsistencies across agencies in various countries, however, remain major challenges in cystic fibrosis (CF) drug development. Clear and consistent treatment guidelines, well educated clinical trial sites, a patient registry and grant funding for early development programs are important success-factors for an efficient development process. SMEs developing products for CF need partners in the CF community to assist with disease education and awareness for ongoing clinical trials. SMEs should collaborate and communicate with the CF community in a legally compliant way to take a patient-centric approach to drug design, development and administration. Furthermore, they can help to develop educational tools and fund medical education activities to increase the understanding of the underlying defects and mechanisms of CF disease. |
| | |
Authors:
|
Miriam Schlangen; Andreas L G Reimann |
Related Documents
:
|
11822749 - Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearanc... 16162009 - Molecular modeling, synthesis, and preliminary biological evaluation of glutathione-s-t... 3277209 - Metabolism of steroid-modifying anticancer agents. 20486069 - Metabolomics: a tool for anticancer lead-finding from natural products. 9166089 - Anticancer drug evaluation: continuing progress from existing methodology. 15155139 - Emerging dna topisomerase inhibitors as anticancer drugs. 18258289 - School-based prevention for illicit drugs use: a systematic review. 235369 - Effects of bretylium and lidocaine on ventricular fibrillation in the isolated rabbit h... 20693049 - Immunotoxicology: an overview. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society Volume: 10 Suppl 2 ISSN: 1873-5010 ISO Abbreviation: J. Cyst. Fibros. Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-06-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101128966 Medline TA: J Cyst Fibros Country: Netherlands |
Other Details:
|
Languages: eng Pagination: S103-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. |
Affiliation:
|
Mukoviszidose Institut gGmbH, 53117 Bonn, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Perspective of clinical research in follicular NHL: Interaction between science and industry.
Next Document: Medical needs of cystic fibrosis patients and policies for fair co-operation between small and middl...